InnoCan Pharma Halts Planned US Listing in Surprise Move

InnoCan Pharma withdraws its SEC registration for a U.S. IPO weeks after approval, citing investor protection. The firm had executed a reverse split to meet listing requirements.

In a sudden reversal, InnoCan Pharma has terminated its long-planned initial public offering in the United States. The Canadian-Israeli pharmaceutical firm pulled its registration for a listing on the NYSE American, leaving investors to question the rationale behind withdrawing at such a late stage.

SEC Filing Formally Withdraws Registration

The company's decision was formalized in a document submitted to the U.S. Securities and Exchange Commission (SEC) on February 23, 2026. InnoCan Pharma filed a request to withdraw its Form F-1 registration statement, effectively shelving its American exchange ambitions for the foreseeable future.

Signed by CEO Iris Bincovich, the filing states the company determined not to proceed with the public offering. The withdrawal is described as being "consistent with the public interest and the protection of investors." No securities were sold under the initial registration. InnoCan also requested that the fees already paid to the SEC be credited for potential future use.

Extensive Preparations Rendered Moot

The abrupt cancellation is particularly unexpected given the significant steps already taken by the company to meet U.S. listing requirements. In August 2025, InnoCan executed a 1-for-65 reverse stock split, a move designed to achieve the minimum share price thresholds mandated by American exchanges.

The process had appeared to be on track. Following an announcement in early January, the IPO date was initially pushed to the end of that month. The SEC even declared the company’s registration effective on February 2, 2026, issuing the standard "EFFECT" notification. The management's choice to abort the entire process merely three weeks after receiving this regulatory green light raises significant questions.

Strategic Rationale Remains Unclear

Beyond the standardized language contained in the SEC filing, InnoCan has not provided detailed reasons for halting the listing. The company has yet to issue a separate press release explaining the strategic considerations behind this decision or outlining alternative plans for accessing U.S. capital markets.

This development comes despite recent operational progress. On February 9, the firm published a peer-reviewed study in the journal Frontiers in Veterinary Science. The research confirmed the pain-relieving efficacy of its LPT-CBD platform in dogs compared to a placebo, marking an important validation for its core technology.

The cancellation does not affect the company's existing listings. InnoCan Pharma shares continue to trade on the Canadian Securities Exchange (CSE) under the ticker "INNO" and on the Frankfurt Stock Exchange. A key focus for investors now is how management intends to address its capital requirements without the anticipated U.S. IPO proceeds and whether the listing project might be revived at a later date.